Who are HZ/su's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): recombinant adjuvanted zoster vaccine, Zoster Vaccine Recombinant, Adjuvanted.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/hz-su.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

HZ/su — Competitive Intelligence Brief

HZ/su (HZ/su) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Recombinant subunit vaccine with adjuvant. Area: Immunology / Infectious Disease.

phase 3 Recombinant subunit vaccine with adjuvant Varicella-zoster virus glycoprotein E (gE) Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

HZ/su (HZ/su) — GlaxoSmithKline. HZ/su is a recombinant zoster vaccine that stimulates immune responses against varicella-zoster virus to prevent herpes zoster (shingles) and post-herpetic neuralgia.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
HZ/su TARGET	HZ/su	GlaxoSmithKline	phase 3	Recombinant subunit vaccine with adjuvant	Varicella-zoster virus glycoprotein E (gE)
recombinant adjuvanted zoster vaccine	recombinant adjuvanted zoster vaccine	Wuerzburg University Hospital	marketed	Recombinant subunit vaccine with adjuvant	Varicella-zoster virus glycoprotein E (gE)
Zoster Vaccine Recombinant, Adjuvanted	Zoster Vaccine Recombinant, Adjuvanted	Wuhan BravoVax Co., Ltd.	marketed	Recombinant subunit vaccine with adjuvant	Varicella-zoster virus glycoprotein E (gE)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Recombinant subunit vaccine with adjuvant class)

GlaxoSmithKline · 1 drug in this class
Wuerzburg University Hospital · 1 drug in this class
Wuhan BravoVax Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). HZ/su — Competitive Intelligence Brief. https://druglandscape.com/ci/hz-su. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab